Market Overview - The veterinary stereotactic radiosurgery system market was valued at USD 3.29 billion in 2024 and is projected to reach USD 7.46 billion by 2032, with a compound annual growth rate (CAGR) of 10.78% from 2025 to 2032 [1][9] Growth Drivers - Key factors driving market growth include the increasing prevalence of cancer in pets, growing awareness among pet owners regarding advanced treatment options, and rapid technological advancements in precision radiation therapy [2] - The U.S. market is expected to grow from USD 1.23 billion in 2024 to USD 2.75 billion by 2032, with a CAGR of 10.65% during the same period [3][4] Market Trends - Major trends include the integration of advanced imaging technologies, improved treatment planning software, and collaborations between veterinary clinics and technology providers [5] - The rising humanization of pets and the willingness of owners to pursue premium treatment options are expected to further accelerate market growth [5] Market Segmentation - By Product: Linear Accelerators (LINAC) held a 52.28% market share in 2024, while Proton Beam Radiation Therapy (PBRT) is the fastest-growing segment with a CAGR of 11.28% [10] - By Application: Tumor treatment dominated the market in 2024, with Neurological Disorders emerging as the fastest-growing segment at a CAGR of 11.68% [11] - By Type: Dogs accounted for 72.94% of the market share in 2024, while small animals are the fastest-growing segment with a CAGR of 12.61% [12][13] - By End-User: Academic & Research Institutions are the largest segment, while Hospitals & Clinics are witnessing the highest growth due to rising pet cancer diagnoses [14] Regional Insights - North America held a dominant market share of 47.60% in 2024, supported by a mature veterinary healthcare system and increased pet ownership [15] - The Asia Pacific region is the fastest-growing area with a CAGR of 11.65%, driven by rising pet ownership and disposable income in countries like China, India, Japan, and South Korea [15] Major Players - Key players in the veterinary stereotactic radiosurgery system market include Xstrahl Ltd, Accuray Incorporated, Varian Medical Systems, and Elekta AB [8]

Group 1: Dick's Sporting Goods - Dick's Sporting Goods, Inc. is currently down 11% from its highs and trades at 11 times earnings [1] - The company reported third-quarter sales of $4.168 billion, reflecting a 36.3% year-over-year increase, surpassing the expected $3.546 billion [2] - Dick's completed its acquisition of Foot Locker in September, with plans to improve the latter's performance [1] Group 2: Intuitive Surgical - Intuitive Surgical, Inc. shares rose 0.9% to close at $561.89 [4] - Truist Securities analyst Richard Newitter maintained a Buy rating on Intuitive Surgical and raised the price target from $620 to $650 [3] Group 3: Toast, Inc. - Toast, Inc. shares rose 3.2% to close at $36.62 [4] - JPMorgan analyst Tien-Tsin Huang upgraded Toast from Neutral to Overweight, maintaining a price target of $43 [3]

Group 1 - HEICO Corporation declared a cash dividend of $0.12 per share, marking its 95th consecutive semiannual cash dividend since 1979 [1][2] - The dividend is payable on January 20, 2026, to shareholders of record on January 5, 2026 [1] - The company's Co-Chairmen expressed pride in the dividend, noting that most team members will receive it in their HEICO 401K plan accounts [2] Group 2 - HEICO Corporation operates in the design, production, servicing, and distribution of products and services for niche segments in aviation, defense, space, medical, telecommunications, and electronics industries [3] - The company serves a diverse customer base, including major airlines, overhaul shops, defense and space contractors, military agencies, and manufacturers in medical and telecommunications sectors [3] - HEICO's next annual meeting of shareholders is scheduled for March 13, 2026, with shareholders of record on January 16, 2026, eligible to vote [2]

Core Insights - TOMI Environmental Solutions, Inc. has secured a significant purchase contract valued at approximately $500,000 from a leading biopharmaceutical company for the integration of its SteraMist Integrated Systems (SIS) platform into critical manufacturing infrastructure [1][2]. Group 1: Contract Details - The purchase order mandates the use of SteraMist iHP technology in passthrough fill boxes, essential for the client's sterile manufacturing and advanced therapeutic production processes [2]. - The SIS platform will provide a fully automated, rapid, and residue-free decontamination solution for critical chambers, with comprehensive installation and performance qualification services included [3]. Group 2: Market Demand and Future Prospects - The SIS platform, launched in late 2024, addresses the growing demand for automated, in-line, and high-throughput decontamination solutions, with a robust pipeline of orders anticipated throughout 2026 and beyond [4]. - The current order is part of a $13 million pipeline for automated installation projects, highlighting the effectiveness of the SIS platform in driving future business [4]. Group 3: Company Overview - TOMI Environmental Solutions, Inc. specializes in decontamination and infection prevention, utilizing its Binary Ionization Technology® (BIT™) platform, which produces a germ-killing aerosol using ionized Hydrogen Peroxide [6]. - The company serves a wide range of commercial structures, including hospitals, medical facilities, and various other environments, demonstrating the versatility of its products [7].

"Company†) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a new durable medical equipment (DME) partnership with 1 Natural Way, a leading national mom-and-baby-focused DME provider. Families nationwide can now access Owlet's FDA-cleared prescription pulse oximeter, BabySat, through insurance-supported pathways on 1NaturalWay.com. Expanding Owlet's DME Reach for Families Who Need It Most 1 Natural Way offers a nation. LEHI, Utah--(BUSINESS WIRE)---- $owlt #babymonitor--Owlet, Inc. (" ...

Core Insights - BD (Becton, Dickinson and Company) has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania to enhance research in deep human immune profiling and support the development of immune-mediated therapies [1][2] Group 1: Collaboration Details - The collaboration aims to develop and validate a high-parameter flow cytometry panel that captures key functional pathways in whole blood, including phosphorylation markers, to provide insights into single-cell responses to drugs or disease states [2] - A planned 1,000-patient immune profiling study will be conducted in partnership with the Penn Colton Center for Autoimmunity, expected to commence in the summer [2] - The project will utilize the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, and BD reagents, with BD teams managing reagents, instrumentation, and spectral data algorithms, while I3H teams will serve as scientific and clinical leads [2] Group 2: Technological Advancements - The BD FACSDiscover™ A8 Cell Analyzer is highlighted as the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, which will facilitate deeper insights into the human immune system [3] - The collaboration reflects a commitment to advancing science and health through the unlocking of the human immune system's potential [3] Group 3: Industry Impact - High-parameter single-cell studies are becoming increasingly central to understanding the human immune system, with BD's ecosystem of flow cytometers, single-cell systems, reagents, software, and informatics providing essential support for organizations like I3H [4] - The collaboration aims to translate immunological insights into quantitative, actionable information for discovery and clinical care teams globally [4]

Shot of Corridor in Working Data Center Full of Rack Servers and Supercomputers with Cloud Storage Advantages Icon Visualization.gettyToday I have a sweet dividend “double shot” for you: The first? A 2.8% payout set to grow thanks to AI—and take the stock price up with it.The second gives you high payouts now, in the form of a monthly-paid 7.8% divvie that also looks set to head higher.Both of these tickers are cheap. In fact, they (and the sector they’re in) could very well be the last bargains on the boar ...

Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com PLAINVIEW, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (OTCQX: VASO) announced today that its wholly owned subsidiary, Vaso Diagnostics, Inc. d/b/a VasoHealthcare, has signed an amendment to the sales representation agreement with GE HealthCare (NASDAQ: GEHC) to extend the term of the agree ...

Core Insights - Sands Capital Global Growth Fund reported a -2.0% return in Q3 2025, underperforming the MSCI ACWI which returned 7.6% [1] - The fund focuses on identifying promising growth companies globally, with a notable emphasis on stocks like Intuitive Surgical, Inc. [2] Company Overview: Intuitive Surgical, Inc. - Intuitive Surgical, Inc. is a leading provider of soft-tissue robotic surgical systems, with a market capitalization of $198.804 billion as of December 16, 2025 [2][3] - The company's stock experienced a one-month return of 3.49% and a 52-week gain of 3.23% [2] Performance Analysis - Despite a decline in stock price during Q3 2025 due to concerns over U.S. hospital budgets, Intuitive Surgical exceeded consensus expectations across all metrics, showcasing strong operating margins [3] - Da Vinci 5 placements increased by 22% quarter-over-quarter, indicating robust demand even before new product launches in the EU and Japan [3] Market Position and Future Outlook - The health care sector, particularly medical equipment, underperformed in Q3 2025, but Intuitive Surgical's fundamentals remained strong [3] - Management's stock repurchase of $180 million reflects confidence in the company's future, as it enters a new robot upgrade cycle [3] - Enthusiasm for robotic cardiothoracic procedures could potentially expand Intuitive's U.S. addressable market by 5 to 10% [3] Hedge Fund Interest - Intuitive Surgical was held by 99 hedge fund portfolios at the end of Q3 2025, a decrease from 107 in the previous quarter, indicating a shift in investor interest [4]

Core Insights - Platinum International Technology Fund reported a 6% increase in Q3 2025, primarily driven by strong performance in AI-oriented holdings [1] - The fund has approximately 30% of its portfolio allocated to AI infrastructure stocks, positioning it to benefit from significant investments in AI development [1] Company Analysis: Intuitive Surgical, Inc. (NASDAQ:ISRG) - The fund increased its position in Intuitive Surgical from 1.5% to 3%, despite the stock experiencing a decline due to a small systems placement miss and competition from lower-priced alternatives [3] - Intuitive Surgical's stock had a one-month return of -1.78% and a 52-week gain of 5.34%, closing at $554.58 with a market capitalization of $198.804 billion on December 16, 2025 [2] - Concerns regarding competition from recycled surgical instruments are mitigated by the preference of surgeons for Intuitive's products based on quality, safety, and reliability, despite a minor cost difference of approximately $50 per surgery [3] Hedge Fund Interest - Intuitive Surgical was held by 99 hedge fund portfolios at the end of Q3 2025, a decrease from 107 in the previous quarter, indicating a shift in interest among hedge funds [4] - While Intuitive Surgical is recognized for its potential, the analysis suggests that certain AI stocks may offer greater upside potential with less downside risk [4]